KRAS is a well-established oncogenic driver whose activating mutations constitutively stimulate the RAF/MEK/ERK and phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathways, thereby promoting uncontrolled proliferation, differentiation abnormalities, drug resistance, and remodeling of the tumor microenvironment [40]. This evidence concerns the gene MAP2K7 and neoplasm.